Expert Opinion on Investigational Drugs

From Wikipedia, the free encyclopedia
This is the current revision of this page, as edited by imported>LightNightLights at 03:34, 11 August 2023 (top: Add italic formatting to normally-italicized text in hatnote to effectively de-italicize it (per WP:ITHAT)). The present address (URL) is a permanent link to this version.
(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Script error: No such module "Hatnote". Template:Infobox Journal Expert Opinion on Investigational Drugs is a monthly peer-reviewed medical journal covering developments in pharmaceutical research, from animal studies through to early clinical investigation. The journal's scope includes therapeutics in many areas: pulmonary-allergy, dermatology, gastrointestinal, arthritis, infectious disorders, endocrine and metabolic, central and peripheral nervous system, cardiovascular and renal, and oncology.

The journal was established by Current Drugs in 1992, under the title Current Opinion in Investigational Drugs. In 1994, the journal was acquired by Ashley Publications, who published it until 2015, when it was acquired by Taylor & Francis. The current Editor-in-Chief is Dr. Naim Alkhouri (Texas Liver Institute, San Antonio, Texas, USA). According to the Journal Citation Reports, the Journal has a 2021 impact factor of 6.498. It is also indexed in MEDLINE. The journal is available online and in paper format.


Template:Pharma-journal-stub